welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Myocardial Involvement in Carriers of Duchenne Muscular Dystrophy: An MRI-study
study id #: NCT01712152
condition: Carrier of Duchenne Muscular Dystrophy
Carriers of Duchenne muscular dystrophy (DMD) often have no severe symptoms of the scelet muscles, but they may develop a poor heart function due to the involvement of the heart muscle. Ultrasound of the heart is recommended, but it can detect a cardiac affection only after the heart has already become weaker. Cardiac magnetic resonance tomography can detect myocardial fibrosis already at preserved heart function and may facilitate early therapy. In our study, diagnosed carriers of DMD will undergo examinations of the heart by blood tests, EKG, heart ultrasound and magnetic resonance at enrollment and after one year in order to assess the extent of cardiac affection and its association with the clinical development.
mechanism of action: No pharmaceutical intervention
last updated: November 22, 2018
start date: October 2012
estimated completion: April 2014
size / enrollment: 20
- T1 mapping [ Time Frame: 1 year ]
T1 mapping by MOLLI sequences will be performed and compared between study entry and one year follow-up
- left ventricular function [ Time Frame: 1 year ]
left ventricular function on MRI will be compared between study entry and one year follow-up
genetic and/or histological identification as a carrier of DMD age above 18 years able and willing to conform to the requirements of the study provided written informed consent exclusion of pregnancy in women of childbearing potential
Claustrophobia Excessive obesity to an extent where CMR cannot be performed Chronic renal failure with a GFR <30 ml/min/1,73m² Implanted pacemakers/defibrillators Severe arrhythmia Inability to cooperate during the CMR Known intolerance to gadolinium Positive pregnancy test Unable or unwilling to conform to the study protocol
A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular DystrophyThis is a first-in-human/first-in-patien...
Unique Burdens of Pediatric Clinical Trials in Duchenne Muscular DystrophyRecent increases in the number and bread...
Safety Study of Flavocoxid in Duchenne Muscular DystrophyObjective of this study is to evaluate s...
Endomysial Fibrosis, Muscular Inflammatory Response and Calcium Homeostasis Dysfunction in Duchenne Muscular Dystrop...Duchenne muscular dystrophy (DMD) is the...
DMD Gene Therapy Clinical Trial: Making a Difference by Gene Replacement (Dr. Jerry Mendell)https://www.youtube.com/watch?v=AeTqv29h...
A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne M...This is a Phase 2 randomized, 2-period, ...
Catabasis Pharmaceuticals Announces Publication Of Phase 1 Clinical Results Of Edasalonexent (CAT-1004) In Duchenne ...Catabasis Pharmaceuticals, Inc., a clini...
The Treatment of Duchenne Muscular Dystrophy: Equipoise, Fidelity and Standardshttps://www.youtube.com/watch?v=ji7Z23qH...
Pfizer Presents Initial Clinical Data on Phase 1b Gene Therapy Study for Duchenne Muscular Dystrophy (DMD)Pfizer Inc. (NYSE:PFE) will present init...